Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·1 day ago, 07:29 AMMPLT+3.08%GS+1.47%
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR StudyMorningStar·Aug 21 at 10:40 AMMPLT+3.08%
Catalyst4 acquires $50.07 million of MapLight Therapeutics common sharesPUBT·Aug 18 at 05:56 PMMPLT+3.08%
MapLight Q2 FY26 net loss widens to $60.19 million; R&D expenses rise to $53.44 millionPUBT·Aug 13 at 03:11 PMMPLT+3.08%
MapLight Therapeutics Announces $150 Million Private Placement FinancingUnusual Whales·Aug 13 at 08:11 AMMPLT+3.08%
MapLight Therapeutics prices USD 150 million PIPE at USD 11.38 a sharePUBT·Aug 13 at 08:10 AMMPLT+3.08%
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down - Time to Sell?Market Beat·Aug 10 at 11:00 AMMPLT+3.08%
Maplight Therapeutics CSO Lillie James Woodruff sells 22,082 shares for $276,908.28PUBT·Aug 4 at 07:40 PMMPLT+3.08%
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS LawPR Newswire·Aug 3 at 01:22 AMMPLT+3.08%
MapLight CEO on what investors missed in the biotech’s schizophrenia databiopharmadive·Jul 31 at 11:22 AMBMY+0.31%MPLT+3.08%
Catalyst4 reports $13.84 million MapLight Therapeutics common share purchasePUBT·Jul 30 at 05:40 PMMPLT+3.08%
